Novel Duchenne muscular dystrophy treatment through myoblast transplantation tolerance with anti-CD45RB, anti-CD154 and mixed chimerism

American Journal of Transplantation

Volumn 4, Issue 8, 2004, Pages 1255-1265

  Camirand, Geoffrey ^a   Rousseau, Joël ^a   Ducharme, Marie Ève ^a   Rothstein, Devid M ^b   Tremblay, Jacques P ^a  

^a LAVAL UNIVERSITY   (Canada)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti CD45RB; Chimerism; Costimulatory blockade; Myoblast transplantation; Tolerance

Indexed keywords

ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CD45 ANTIGEN; CD45RB ANTIBODY; DYSTROPHIN; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSPLANTATION; CHIMERA; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG POTENTIATION; DUCHENNE MUSCULAR DYSTROPHY; FATALITY; GRAFT SURVIVAL; MOUSE; MYOBLAST; MYOBLAST TRANSPLANTATION; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; RADIATION DOSE; SKIN TRANSPLANTATION; TRANSPLANTATION TOLERANCE; WHOLE BODY RADIATION;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; BONE MARROW TRANSPLANTATION; CD40 LIGAND; CELL TRANSPLANTATION; CHIMERA; DYSTROPHIN; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCLES; MUSCULAR DYSTROPHY, DUCHENNE; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION TOLERANCE;

EID: 3543006599     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00501.x     Document Type: Article

References (44)

1. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
2. Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 1989; 337: 176-179.
3. Skuk D, Tremblay JP. Progress in myoblast transplantation: a potential treatment of dystrophies. Microsc Res Tech 2000; 48: 213-222.
4. Kinoshita I, Vilquin JT, Guerette B, Asselin I, Roy R, Tremblay JP. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 1994; 17: 1407-1415.
5. Alameddine HS, Louboutin JP, Dehaupas M, Sebille A, Fardeau M. Functional recovery induced by satellite cell grafts in irreversibly injured muscles. Cell Transplant 1994; 3: 3-14.
6. Brussee V, Merly F, Tardif F, Tremblay JP. Normal myoblast implantation in MDX mice prevents muscle damage by exercise. Biochem Biophys Res Commun 1998; 250: 321-327.
7. Irintchev A, Langer M, Zweyer M, Theisen R, Wernig A. Functional improvement of damaged adult mouse muscle by implantation of primary myoblasts. J Physiol 1997; 500: 775-785.
8. Guerette B, Roy R, Tremblay M et al. Increased granzyme B mRNA after alloincompatible myoblast transplantation. Transplantation 1995; 60: 1011-1016.
9. Huard J, Roy R, Guerette B, Verreault S, Tremblay G, Tremblay JP. Human myoblast transplantation in immunodeficient and immunosuppressed mice: evidence of rejection. Muscle Nerve 1994; 17: 224-234.
10. Kinoshita I, Roy R, Dugre FJ et al. Myoblast transplantation in monkeys: control of immune response by FK506. J Neuropathol Exp Neurol 1996; 55: 687-697.
11. Markees TG, Phillips NE, Noelle RJ et al. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Transplantation 1997; 64: 329-335.
12. Larsen CP, Alexander DZ, Hollenbaugh D et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996; 61: 4-9.
13. Parker DC, Greiner DL, Phillips NE et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A 1995; 92: 9560-9564.
14. Basadonna GP, Auersvald L, Khuong CQ et al. Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci U S A 1998; 95: 3821-3826.
15. Lazarovits AI, Poppema S, Zhang Z et al. Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 1996; 380: 717-720.
16. Rothstein DM, Livak MF, Kishimoto K et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001; 166: 322-329.
17. Camirand G, Caron NJ, Turgeon NA, Rossini AA, Tremblay JP. Treatment with anti-CD154 antibody and donor-specific transfusion prevents acute rejection of myoblast transplantation. Transplantation 2002; 73: 453-461.
18. Guerette B, Gingras M, Wood K, Roy R, Tremblay JP. Immunosuppression with monoclonal antibodies and CTLA4-Ig after myoblast transplantation in mice. Transplantation 1996; 62: 962-967.
19. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168-170.
20. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14: 417-424.
21. Ito H, Kurtz J, Shaffer J, Sykes M. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol 2001; 166: 2970-2981.
22. Wekerle T, Sayegh MH, Hill J et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187: 2037-2044.
23. Cossu G, Zani B, Coletta M, Bouche M, Pacifici M, Molinaro M. In vitro differentiation of satellite cells isolated from normal and dystrophic mammalian muscles. A comparison with embryonic myogenic cells. Cell Differ 1980; 9: 357-368.
24. Wakeford S, Watt DJ, Partridge TA. X-irradiation improves mdx mouse muscle as a model of myofiber loss in DMD. Muscle Nerve 1991; 14: 42-50.
25. Harris JB, Johnson MA, Karisson E. Proceedings: Histological and histochemical aspects of the effect of notexin on rat skeletal muscle. Br J Pharmacol 1974; 52: 152P.
26. Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 1979; 150: 580-596.
27. Hoffman EP, Morgan JE, Watkins SC, Partridge TA. Somatic reversion/suppression of the mouse mdx phenotype in vivo. J Neurol Sci 1990; 99: 9-25.
28. Tomita Y, Khan A, Sykes M. Mechanism by which additional monoclonal antibody (mAB) injections overcome the requirement for thymic irradiation to achieve mixed chimerism in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation. Transplantation 1996; 61: 477-485.
29. Durham MM, Bingaman AW, Adams AB et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 1-4.
30. Taylor PA, Lees CJ, Waldmann H, Noelle RJ, Blazar BR. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001; 98: 467-474.
31. Lee JY, Qu-Petersen Z, Cao B et al. Cional isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol 2000; 150: 1085-1100.
32. Ferrari G, Cuselia-De Angelis G, Coletta M et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528-1530.
33. Gussoni E, Soneoka Y, Strickland CD et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999; 401: 390-394.
34. Gussoni E, Bennett RR, Muskiewicz KR et al. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest 2002; 110: 807-814.
35. LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 2002; 111: 589-601.
36. Skuk D, Goulet M, Roy B, Tremblay JP. Myoblast transplantation in whole muscle of nonhuman primates. J Neuropathol Exp Neurol 2000; 59: 197-206.
37. Garlepp MJ, Chen W, Tabarias H, Baines M, Brooks A, McCluskey J. Antigen processing and presentation by a murine myoblast cell line. Clin Exp Immunol 1995; 102: 614-619.
38. Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myoblasts as antigen-presenting cells. J Immunol 1992; 149: 661-667.
39. Curnow J, Corlett L, Willcox N, Vincent A. Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. J Neuroimmunol 2001; 115: 127-134.
40. Vilquin JT, Wagner E, Kinoshita I, Roy R, Tremblay JP. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin. J Cell Biol 1995; 131: 975-988.
41. Fecteau S, Basadonna GP, Freitas A, Ariyan C, Sayegh MH, Rothstein DM. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat Immunol 2001; 2: 58-63.
42. Trambley J, Bingaman AW, Lin A et al. Asialo GM1 (+) CD8 (+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999; 104: 1715-1722.
43. Shirasugi N, Adams AB, Durham MM et al. Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism-and nonchimerism- inducing costimulation blockade-based tolerance induction regimens. J Immunol 2002; 169: 2677-2684.
44. Ohtsuka Y, Udaka K, Yamashiro Y, Yagita H, Okumura K. Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: implication for gene therapy. J Immunol 1998; 160: 4635-4640.